Compare Goldman Sachs Group Inc (GS) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs Nuwellis Inc — how do they compare? Goldman Sachs Group Inc trades at $1,090.55 (market cap $339.87B), while Nuwellis Inc trades at $2.85 (market cap $1.10M). The key difference: Goldman Sachs Group Inc is far larger — about 308972.7× Nuwellis Inc's market cap, and Goldman Sachs Group Inc pays a 1.56% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| GS | NUWE | |
|---|---|---|
Market Cap | $339.87B | $1.10M |
Volume | 2,592,735 | — |
Sector | Financials | Technology |
52-Week High | $1.15K | $558.26 |
52-Week Low | $700.41 | $2.80 |
Dividend Yield | 1.56% | — |
Enterprise Value | — | -$709.83K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,140, up 9.0% over 24 hours, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $20.98 versus $14.47, and revenue growth from $58.28B in 2025 to $60.4B projected for 2026. Recent news highlights Goldman's role in leading high-profile IPOs including Anthropic, signaling strong investment banking pipeline strength.
Outlook remains positive with analyst consensus price target of $1,140K and 40% buy ratings, though RSI levels suggest potential near-term overbought conditions. Key risks include volatile cash flow patterns and high leverage, while institutional sentiment supports continued growth from M&A activity and AI-driven market opportunities.
Nuwellis (NUWE) trades at $2.85, down 11.49% in the last session, reflecting ongoing financial challenges despite recent strategic initiatives. The stock shows a bearish technical outlook with negative cash flow and widening losses, though it maintains a high gross margin of 65.47%. Recent corporate actions include a 35:1 reverse stock split in June 2026 and a $6 million public offering to fund operations.
The outlook remains challenging with significant losses and negative profitability metrics, though new CEO leadership and patent developments offer potential catalysts. Investment opportunities exist in the company's niche pediatric cardiorenal market, while risks include cash burn, execution challenges, and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
